Major reversal coming soon to a bank account near you
Recent BBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:26:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 08:24:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:01:37 PM
- Wall Street's Cardiac Bet: Where Diagnostics Meet the Money • PR Newswire (US) • 05/12/2026 12:30:00 PM
- Wall Street's Cardiac Bet: Where Diagnostics Meet the Money • PR Newswire (Canada) • 05/12/2026 12:30:00 PM
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 • GlobeNewswire Inc. • 05/12/2026 11:30:00 AM
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure • GlobeNewswire Inc. • 05/11/2026 01:30:00 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/08/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 01:01:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:31:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:02:53 PM
- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 08:01:00 PM
- BridgeBio to Participate in May and June Investor Conferences • GlobeNewswire Inc. • 05/06/2026 08:01:00 PM
- BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil • GlobeNewswire Inc. • 05/06/2026 11:30:00 AM
- BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE • GlobeNewswire Inc. • 05/05/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:22:25 PM
- BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 • GlobeNewswire Inc. • 05/04/2026 11:30:00 AM
- BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:26:28 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:25:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:25:16 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/22/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:30:36 PM
